---
title: "Moderna could begin manufacturing unproven coronavirus vaccine in July, CEO says"
description: "Stephane Bancel, chief executive officer of Moderna Therapeutics Inc., sits for a photograph at the company's office in Cambridge, Massachusetts.Adam Glanzman | Bloomberg | Getty ImagesModerna hopes t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/13029865.md"
published_at: "2020-05-01T12:59:41.000Z"
---

# Moderna could begin manufacturing unproven coronavirus vaccine in July, CEO says

> Stephane Bancel, chief executive officer of Moderna Therapeutics Inc., sits for a photograph at the company's office in Cambridge, Massachusetts.Adam Glanzman | Bloomberg | Getty ImagesModerna hopes to begin manufacturing its as-yet unapproved coronavirus vaccine "as early as July," CEO Stephane Bancel told CNBC Friday ... The company is pushing forward with manufacturing the potential vaccine, called mRNA-1273, in hopes that it proves safe for humans and effective against the coronavirus ... Mo

Stephane Bancel, chief executive officer of Moderna Therapeutics Inc., sits for a photograph at the company's office in Cambridge, Massachusetts.

Adam Glanzman | Bloomberg | Getty Images

Moderna hopes to begin manufacturing its as-yet unapproved coronavirus vaccine "as early as July," CEO Stephane Bancel told CNBC Friday.

The biotech company announced earlier Friday a 10-year partnership with Swiss drugmaker Lonza to accelerate manufacturing of the experimental vaccine.

"We are hoping with Lonza to start making product for the corona vaccine as early as July," Bancel said on CNBC's "Squawk Box." "Our team is ready to start dosing as soon as we get the green light."

The company is pushing forward with manufacturing the potential vaccine, called mRNA-1273, in hopes that it proves safe for humans and effective against the coronavirus. However, the vaccine candidate remains in phase 1 trial. 

The potential vaccine, which was developed by researchers at Moderna and the National Institutes of Health, became the first candidate to enter a phase 1 human trial in March and full results have not been released. Bancel added that data from the phase 1 trial "looks positive" with regards to safety.

Earlier this week, Moderna announced it has submitted an application to the Food and Drug Administration to move the candidate to phase 2 trial. The company says a phase 3 trial could begin as soon as fall of 2020. 

The NIH said their researchers were able to quickly produce a candidate with Moderna because the two organizations were already partnered, researching "related coronaviruses."

Moderna, as well as other companies in the race to develop a vaccine for the coronavirus, is ramping up manufacturing ahead of approval so that it can rapidly distribute doses if their candidate proves effective against the virus. Bancel said his team on their own could manufacture about 100 million doses per year, but with the Lonza partnership, they hope to produce about 1 billion doses per year.

"If you can only make a few million vials, it's not going to be really helping the global public health issue we have," he said. "Our goal is to make the vaccine available around the world."

Last month, Moderna announced it received a $483 million contract from the Biomedical Advanced Research and Development Authority to accelerate the development of its vaccine candidate. Shares of Moderna rose more than 15% on the news.

The vaccine uses synthetic messenger RNA to inoculate against the virus. Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.

The race to develop a vaccine is intensely competitive and investors are watching closely for signs of progress on treatments and vaccines. Bancel said it will take more than one company to beat back the coronavirus, which has infected more than 3.2 million people around the world and killed at least 230,000.

"No one company can help the entire planet," he said.

### Related Stocks

- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 全球人工智慧峯會呼籲打造安全可信強健 AI | 在新德裡舉行的全球人工智慧峯會閉幕，86 個國家及 2 個國際組織發布聯合宣言，呼籲發展安全、可信且強健的 AI。會議討論生成式 AI 的影響，強調節能 AI 系統的重要性，並提出自願性倡議以整合國際 AI 研究能力。宣言指出，AI 的益處 | [Link](https://longbridge.com/en/news/276518719.md) |
| 高院否決，特朗普將被迫退税！華爾街 “早就下注”，商務部長兒子甚至一度參與 | 去年 10 月投資機構以每美元 20-40 美分的折扣價從進口商手中購入關税退款索賠權，單筆交易規模多在 200 萬至 2000 萬美元。投資者有望獲得超 8 倍回報。但退款前景仍存不確定性，涉及金額達數十億美元，各方仍在觀望。 | [Link](https://longbridge.com/en/news/276502404.md) |
| Aithor 推出 AI 檢測器，以幫助教育工作者和學生識別由 AI 生成的文本 | Aithor 是一家總部位於愛沙尼亞的人工智能技術公司，推出了一款 AI 檢測器，這是一種基於網絡的工具，幫助用户識別 AI 生成的寫作內容。該工具旨在為教育工作者、學生和專業人士評估書面內容的原創性，以應對對 AI 輔助寫作透明度日益增長 | [Link](https://longbridge.com/en/news/276503971.md) |
| SK 海力士高盛電話會：所有客户需求都無法滿足，今年存儲價格持續上漲 | SK 海力士在高盛電話會上釋放強烈信號：存儲行業已全面進入賣方市場。受 AI 真實需求驅動及潔淨室空間受限影響，今年存儲價格將持續上漲。公司透露目前 DRAM 及 NAND 庫存僅剩約 4 周，且沒有任何客户能完全滿足需求。隨着 2026  | [Link](https://longbridge.com/en/news/276505903.md) |
| Usha Resources 將安大略省的 Rubidium Ridge 項目的選擇權授予 Panther Minerals | Usha Resources 已與 Panther Minerals 簽署協議，收購其位於安大略省的 Rubidium Ridge 項目的 100% 權益。這標誌着 Usha 第三次剝離非核心資產，使公司能夠專注於其 Southern Ar | [Link](https://longbridge.com/en/news/276500712.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.